FRONTLINE investigates how El Paso, Texas became the Trump administration's immigration testing ground, and the target of a white supremacist. Interviews tell the inside story from the epicenter of the border crisis.

Barack Obama's promise of unity collapsed as increasing racial, cultural and political divisions laid the groundwork for the rise of Donald Trump.

Part Two examines how Trump's campaign exploited the country's divisions, how his presidency has unleashed anger on both sides of the divide, and what America's polarization could mean for the country's future.

Know what this is about?
Be the first one to add a plot.

With unique access inside the battle for Hong Kong, FRONTLINE follows five protesters through the most intense clashes over several months of pro-democracy protests. The film examines their struggle against growing influence from the communist government of China.

Examine Amazon CEO Jeff Bezos' ascent to power and the global impact of the empire he built. The film also investigates the darker side of the company's rapid growth, and the challenge of trying to rein in the power of the richest man in the world.

As the 2020 election approaches, the once-unrivaled National Rifle Association is facing both internal strife and a rising external threat: a movement led by student survivors of the Parkland mass shooting. FRONTLINE investigates the status of America's gun debate - and why the organization that has dominated it for so long is now under attack on all sides.

Plastic Wars With the plastic industry expanding like never before, and the crisis of ocean pollution growing, FRONTLINE and NPR investigate the fight over the future of plastics.

Doctors in Northern Italy are forced to make life and death decisions regarding patients infected with COVID-19; how the coronavirus outbreak impacts families in the U.S. who are already facing poverty.

The story of a drug company that pushed opioids by bribing doctors and committing insurance fraud. With the Financial Times, an investigation of how Insys Therapeutics profited from a fentanyl-based painkiller 50 times stronger than heroin.